Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WANBURY.NS
BuyFull HouseWanbury Limited · Healthcare · India · $91M · Avg Vol: $913K/d
69
StockRankGet insider-trade alerts
Q
60
V
50
M
55
P/E (TTM)
15.0x
ROE
45.8%
D/E
1.6x
Dividend %
—
COMPANY DESCRIPTION
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 5.0B | 5.7B | 5.9B | 6.4B | 8.9% | 3.7B |
| EPS (INR) | -3.18 | 17.10 | 9.32 | 19.49 | 6.8% | 16.30 |
| Shares | 32.7M | 32.7M | 32.8M | 34.9M | +6.8% | 35.0M |
| Debt | 1.1B | 1.2B | 1.8B | 2.2B | 27.4% | 2.2B |
| Equity | -328.2M | 279.4M | 592.7M | 1.4B | 127.4% | — |
| Op CF | 198.0M | 47.0M | 262.0M | 315.3M | 16.8% | 315.3M |
| Inv CF | -88.4M | -166.3M | -511.7M | -564.0M | — | — |
| Fin CF | -319.9M | 138.7M | 256.3M | 224.2M | — | — |
Loading 1Y...
PRICE (1Y)-20.0%
SMA 50SMA 200
Close
$2.57
RSI (14)
22.2
52W High
$3.77
From 52W High
0.7%
SCORE BREAKDOWN
Quality
60
ROIC
25.6%94.7
ROE
45.8%97.1
GP/Assets
34.7%70.4
Op. Margin
5.5%53.4
FCF/Assets
-5.3%34.8
Piotroski
668.8
Int. Cover
2.7x45.0
D/E Ratio
1.55x7.9
Current Ratio
1.19x16.3
Value
50
P/E (TTM)
15.0x73.5
EV/EBITDA
10.4x68.5
P/FCF
—N/A
P/B
5.1x28.2
P/S
2.3x64.1
Div Yield
—N/A
Momentum
55
52W High %
68%46.0
RS 6M
4%68.3
SMA 50/200
1.10x76.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$91M
P/E (Forward)
—
Gross Margin
48.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WANBURY.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WANBURY.NS | Wanbury Limited(you) | $91M | 69 | Buy |
| ZIMLAB.NS | ZIM Laboratories Limited | $73M | 67 | Buy |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 81 | Strong Buy |
| THEMISMED.NS | Themis Medicare Limited | $129M | 62 | Hold |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $120M | 59 | Hold |
| KILITCH.NS | Kilitch Drugs (India) Limited | $69M | 58 | Hold |
| BAFNAPH.NS | Bafna Pharmaceuticals Limited | $77M | 55 | Hold |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%